Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCMSC-derived exosomes for Crohn's disease with refractory perianal fistula
ChiCTR2500099956Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Apr 2025
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human umbilical cord mesenchymal stem cell-derived exosomes in Crohn's disease, sponsored by First Affiliated Hospital of Xiamen University. Primary endpoints: PDAI score at 24 months and Clinical fistula healing rate at 24 months. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cell-derived exosomes
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on ChiCTR2500099956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099956.